Categories: News

Dr. Matthew Kalady Joins Activ Surgical Advisory Board

BOSTON, Dec. 11, 2020 /PRNewswire/ — Activ Surgical™, a digital surgery pioneer, today announced that Dr. Matthew Kalady, Chief of the Colon and Rectal Surgery Division at the Ohio State University College of Medicine, has joined Activ Surgical’s Advisory Board. The Activ Surgical Advisory Board is comprised of the foremost experts spanning various areas of surgical specialty, and is instrumental in advising the company on product strategy and development.

“We are thrilled to have Dr. Kalady, a proven expert and leader in the field of colorectal surgery, join our Advisory Board,” said Todd Usen, Chief Executive Officer, Activ Surgical. “He is a highly regarded surgeon focused on providing best-in-class patient care and dedicated to improving patient outcomes, which is directly aligned with our corporate mission. His expertise will be invaluable to Activ Surgical in providing insights on the use of our products in colorectal surgery, which is one of our initial areas of focus as we move toward commercial availability of our first product, ActivSight.”

Dr. Kalady is board certified by the American Board of Colon and Rectal Surgeons and the American Board of Surgery. A longtime expert in colorectal surgery, he currently serves as Chief of the Colon and Rectal Surgery Division at the Ohio State University College of Medicine and was previously Vice-Chairman of the Department of Colorectal Surgery at the Cleveland Clinic. He joined the Cleveland Clinic in 2006, and held a variety of leadership roles there, including Co-director of the Comprehensive Colorectal Cancer Program; Director for the National Accreditation Program for Rectal Cancer Team; Director for the Sanford R. Weiss, MD, Center for Hereditary Colorectal Neoplasia; James Church, MD, and Edward J. Bartolo, Jr. Family Endowed Chair in Colorectal Surgery; and Professor of Surgery.

“I’m excited to join the respected group of clinicians and experts on Activ Surgical’s Advisory Board, and I look forward to working with Todd and the leadership team,” said Dr. Matthew Kalady. “I am confident that Activ Surgical’s innovative platform and collaborative approach will not only improve patient outcomes and safety, but revolutionize the surgical field.”

In addition to these leadership roles, Dr. Kalady is a National Cancer Institute/National Institutes of Health-funded researcher in colorectal cancer genetics. He has authored more than 200 peer-reviewed publications and has served as an editor for colorectal surgery textbooks. He is a member of the American Surgical Association, the Society of Clinical Surgery and the Commission on Cancer, and serves as Chair of the International Society for Gastrointestinal Hereditary Tumours (InSiGHT). He is also a fellow of the American Society of Colon and Rectal Surgeons, as well as the American College of Surgeons. He serves on the editorial boards of Diseases of the Colon & Rectum, Annals of Surgery and British Journal of Surgery. Dr. Kalady earned his M.D from the Duke University School of Medicine and completed his surgical residency and a research fellowship at Duke University Medical Center. Additionally, he completed a colorectal surgery residency at the Cleveland Clinic. He also holds a B.A. from Harvard University.

Dr. Kalady joins the following esteemed individuals on the Activ Surgical Advisory Board:

  • Dr. Uma Duvvuri, Director of Robotic Head & Neck Surgery; Assistant Professor, Department of Otolaryngology, UPMC.
  • John Galeotti, PhD., Director of the Biomedical Image Guidance Laboratory, Carnegie Mellon University (CMU).
  • Dr. Adrian Park, Chairman of the Department of Surgery, Anne Arundel Medical Center; Professor of Surgery, Johns Hopkins University School of Medicine.
  • Dr. Vipul Patel, Medical Director, Global Robotics Institute, Advent Health; Founding member of Society of Robotics Surgery.
  • Dr. Steven Schwaitzberg, Professor and Chairman – Department of Surgery, University at Buffalo.
  • Dr. Erik Wilson, Medical Director of Bariatric Surgery, Memorial Hermann-Texas Medical Center; Professor in the Department of Surgery, University of Texas Medical School at Houston; Director, Minimally Invasive Surgeons of Texas (MIST).

For more information on Activ Surgical, please visit https://www.activsurgical.com/#about.

About Activ Surgical  

Activ Surgical, the company that completed the world’s first autonomous robotic surgery of soft tissue, is building hardware-agnostic surgical software that allows surgical systems to collaborate with surgeons. Activ Surgical’s patent-protected surgical software platform reduces unintended and preventable surgical complications by enhancing a surgeon’s intra-operative decision making. Activ Surgical is privately held, and backed by DNS Capital, GreatPoint Ventures (GPV), Artis Ventures, Tao Capital Partners, LRVHealth, Rising Tide VC, SONY Innovation Fund and 8VC. More information can be found at www.activsurgical.com.

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/dr-matthew-kalady-joins-activ-surgical-advisory-board-301191053.html

SOURCE Activ Surgical

Staff

Recent Posts

CannaPharmaRX Provides Corporate Update and Outlines Growth Strategy for 2026

CALGARY, AB / ACCESS Newswire / January 12, 2026 / CannaPharmaRX, Inc. (OTC PINK:CPMD), an…

6 hours ago

TempraMed Closes C$2.5 Million Fully Subscribed Private Placement

Vancouver, British Columbia--(Newsfile Corp. - January 12, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE:…

9 hours ago

TruuCONNECT NJ Statewide Digital Hub Empowers Users to Find Verified, Local Community Resources and Support – Anonymously and in Real Time

MOUNT LAUREL, N.J., Jan. 12, 2026 /PRNewswire/ -- Born out of a partnership between the…

9 hours ago

Nuvo Unveils Large-Scale AI-Ready Pregnancy Dataset Built on Real-World Maternal and Fetal Physiology

Unique longitudinal dataset combining native fetal and maternal ECG with phonocardiography supports deeper insights into…

9 hours ago

Alamar Biosciences Announces Launch of NULISAqpcr™ AD 5-plex Assay, Advancing Blood Based Biomarker Detection in Alzheimer’s Disease Research

FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision…

9 hours ago

RxAnte Announces Strategic Growth Investment from Primus Capital

PORTLAND, Maine, Jan. 12, 2026 /PRNewswire/ -- RxAnte, the leading provider of analytics, software, and…

9 hours ago